10 Participants Needed

Psilocybin for Bipolar Disorder

TM
LV
JC
Overseen ByJair C. Soares, MD, PhD
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: The University of Texas Health Science Center, Houston
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 2 JurisdictionsThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

The purpose of the study is to assess the safety and acceptability of up to two sequential administrations of 25 mg psilocybin with additional therapeutic support in decreasing suicidality in patients with Bipolar Disorder (BD II) depression.

Research Team

TM

Thomas Meyer, PhD

Principal Investigator

The University of Texas Health Science Center, Houston

Eligibility Criteria

This trial is for individuals with Bipolar Disorder II who are experiencing depression and may have suicidal thoughts. Participants must be stable on their current medications and in good physical health to handle the psilocybin treatment.

Inclusion Criteria

Must have completed written informed consent
I have been diagnosed with depression based on MADRS scores.
Ability to comply with all study visits
See 7 more

Exclusion Criteria

Active suicidal ideation with at least some intent and/or plan
A close family member has Bipolar I or a psychotic disorder.
History of medically significant suicide attempt in the last 6 months
See 4 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive up to two sequential doses of 25 mg psilocybin with therapeutic support

3 weeks
Multiple visits for administration and therapeutic support

Follow-up

Participants are monitored for safety and effectiveness after treatment

3 weeks
Follow-up visits to assess outcomes

Treatment Details

Interventions

  • Psilocybin
Trial Overview The study is testing if taking up to two doses of 25 mg psilocybin, along with therapeutic support, can reduce suicidality in patients with Bipolar Disorder II depression.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Psilocybin with therapeutic supportExperimental Treatment2 Interventions
Up to two sequential administrations of 25 mg psilocybin with additional therapeutic support.

Psilocybin is already approved in United States, European Union for the following indications:

🇺🇸
Approved in United States as Psilocybin for:
  • Treatment-resistant depression (TRD) under Breakthrough Therapy designation
🇪🇺
Approved in European Union as Psilocybin for:
  • Treatment-resistant depression (TRD) under PRIME designation

Find a Clinic Near You

Who Is Running the Clinical Trial?

The University of Texas Health Science Center, Houston

Lead Sponsor

Trials
974
Recruited
361,000+

Anne and Don Fizer Foundation

Collaborator

Trials
1
Recruited
10+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security